CN101317852B - 一种复方甘草酸苷类粉针注射剂及其制备方法 - Google Patents
一种复方甘草酸苷类粉针注射剂及其制备方法 Download PDFInfo
- Publication number
- CN101317852B CN101317852B CN2008101157160A CN200810115716A CN101317852B CN 101317852 B CN101317852 B CN 101317852B CN 2008101157160 A CN2008101157160 A CN 2008101157160A CN 200810115716 A CN200810115716 A CN 200810115716A CN 101317852 B CN101317852 B CN 101317852B
- Authority
- CN
- China
- Prior art keywords
- injection
- add
- prescription
- glycoside
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002347 injection Methods 0.000 title claims abstract description 99
- 239000007924 injection Substances 0.000 title claims abstract description 99
- 239000000843 powder Substances 0.000 title claims abstract description 53
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 title claims abstract description 33
- 229960004949 glycyrrhizic acid Drugs 0.000 title claims abstract description 33
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 title claims abstract description 33
- 235000019410 glycyrrhizin Nutrition 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 title claims abstract description 20
- 239000001685 glycyrrhizic acid Substances 0.000 title claims abstract description 20
- 229930182470 glycoside Natural products 0.000 title claims description 93
- -1 compound glycyrrhizic acid glycosides Chemical class 0.000 title claims description 30
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 108
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 claims abstract description 68
- 229960001305 cysteine hydrochloride Drugs 0.000 claims abstract description 67
- 239000004471 Glycine Substances 0.000 claims abstract description 54
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 claims abstract description 49
- 150000001875 compounds Chemical class 0.000 claims abstract description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 75
- 150000002338 glycosides Chemical class 0.000 claims description 74
- 239000000243 solution Substances 0.000 claims description 74
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 69
- 239000000047 product Substances 0.000 claims description 62
- 239000000203 mixture Substances 0.000 claims description 59
- 238000009472 formulation Methods 0.000 claims description 58
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 44
- 239000008215 water for injection Substances 0.000 claims description 44
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 42
- 238000003756 stirring Methods 0.000 claims description 41
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 35
- 229940119744 dextran 40 Drugs 0.000 claims description 30
- 239000007788 liquid Substances 0.000 claims description 29
- 238000013019 agitation Methods 0.000 claims description 27
- 229940101006 anhydrous sodium sulfite Drugs 0.000 claims description 27
- 239000002253 acid Substances 0.000 claims description 26
- 229910052799 carbon Inorganic materials 0.000 claims description 18
- 238000004821 distillation Methods 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 13
- 238000012856 packing Methods 0.000 claims description 13
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 229950004777 sodium calcium edetate Drugs 0.000 claims description 12
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 11
- 239000003610 charcoal Substances 0.000 claims description 9
- 239000002738 chelating agent Substances 0.000 claims description 9
- 229910052751 metal Inorganic materials 0.000 claims description 9
- 239000002184 metal Substances 0.000 claims description 9
- 239000011265 semifinished product Substances 0.000 claims description 9
- 239000003963 antioxidant agent Substances 0.000 claims description 8
- 230000003078 antioxidant effect Effects 0.000 claims description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 238000011068 loading method Methods 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 229960002433 cysteine Drugs 0.000 claims description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 5
- 235000018417 cysteine Nutrition 0.000 claims description 5
- 230000002328 demineralizing effect Effects 0.000 claims description 4
- 238000000465 moulding Methods 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 87
- 239000003814 drug Substances 0.000 abstract description 25
- 229920002307 Dextran Polymers 0.000 abstract description 17
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract description 16
- 230000008569 process Effects 0.000 abstract description 14
- 239000004378 Glycyrrhizin Substances 0.000 abstract description 13
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 238000003860 storage Methods 0.000 abstract description 3
- 229960001269 glycine hydrochloride Drugs 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 229940090044 injection Drugs 0.000 description 82
- 238000005516 engineering process Methods 0.000 description 67
- 238000012360 testing method Methods 0.000 description 51
- 229960002449 glycine Drugs 0.000 description 47
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 34
- 239000000523 sample Substances 0.000 description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 239000011780 sodium chloride Substances 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 12
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 11
- 229930195725 Mannitol Natural products 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- 239000000594 mannitol Substances 0.000 description 11
- 235000010355 mannitol Nutrition 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- 238000001035 drying Methods 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000003908 quality control method Methods 0.000 description 8
- 206010018910 Haemolysis Diseases 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000008588 hemolysis Effects 0.000 description 7
- 230000007774 longterm Effects 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 238000004448 titration Methods 0.000 description 7
- 238000007689 inspection Methods 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 238000010792 warming Methods 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 229920005549 butyl rubber Polymers 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000011010 flushing procedure Methods 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 229940093181 glucose injection Drugs 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- 229940126680 traditional chinese medicines Drugs 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 239000002510 pyrogen Substances 0.000 description 4
- 229940001482 sodium sulfite Drugs 0.000 description 4
- 235000010265 sodium sulphite Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000002949 hemolytic effect Effects 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 229960001855 mannitol Drugs 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000008354 sodium chloride injection Substances 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 102000003820 Lipoxygenases Human genes 0.000 description 2
- 108090000128 Lipoxygenases Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000006666 Shwartzman Phenomenon Diseases 0.000 description 2
- 231100000702 Shwartzman phenomenon Toxicity 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229940121657 clinical drug Drugs 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000011082 depyrogenation Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000007365 immunoregulation Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229940105082 medicinal charcoal Drugs 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 101100515508 Arabidopsis thaliana XI-D gene Proteins 0.000 description 1
- 208000000104 Arthus reaction Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001411320 Eriogonum inflatum Species 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 231100000643 Substance intoxication Toxicity 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229940083975 glycine 200 mg Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- LGZXYFMMLRYXLK-UHFFFAOYSA-N mercury(2+);sulfide Chemical compound [S-2].[Hg+2] LGZXYFMMLRYXLK-UHFFFAOYSA-N 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- FPLYNRPOIZEADP-UHFFFAOYSA-N octylsilane Chemical group CCCCCCCC[SiH3] FPLYNRPOIZEADP-UHFFFAOYSA-N 0.000 description 1
- 230000010494 opalescence Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940083618 sodium nitroprusside Drugs 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 230000008359 toxicosis Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
1 | 2 | 3 | 4 | 5 | 6 | 7 | |
供试品(ml) | 0.1 | 0.2 | 0.3 | 0.4 | 0.5 | ||
生理盐水(ml) | 2.4 | 2.3 | 2.2 | 2.1 | 2.0 | 2.5 | 蒸馏水 |
2%细胞悬液(ml) | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 |
15分钟 | - | - | - | - | - | - | + |
30分钟 | - | - | - | - | - | - | + |
45分钟 | - | - | - | - | - | - | + |
1小时结果 | - | - | - | - | - | - | + |
2小时结果 | - | - | - | - | - | - | + |
3小时结果 | - | - | - | - | - | - | + |
4小时结果 | - | - | - | - | - | - | + |
组别 | 时间 | 动物数(只) | 阳性率(%) |
给药组 | 14日 | 3 | 0 |
阳性组 | 14日 | 3 | 100 |
给药组 | 21日 | 3 | 0 |
阳性组 | 21日 | 3 | 100 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101157160A CN101317852B (zh) | 2008-06-27 | 2008-06-27 | 一种复方甘草酸苷类粉针注射剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101157160A CN101317852B (zh) | 2008-06-27 | 2008-06-27 | 一种复方甘草酸苷类粉针注射剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101317852A CN101317852A (zh) | 2008-12-10 |
CN101317852B true CN101317852B (zh) | 2010-06-30 |
Family
ID=40178291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008101157160A Active CN101317852B (zh) | 2008-06-27 | 2008-06-27 | 一种复方甘草酸苷类粉针注射剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101317852B (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101791295B (zh) * | 2010-02-24 | 2012-07-11 | 王保明 | 复方甘草酸单铵s药物组合物及其冻干粉针剂制备方法 |
CN102526082B (zh) * | 2011-12-16 | 2013-05-29 | 南京农业大学 | 一种畜禽用复方甘草酸单胺可溶性粉剂及其制备方法 |
CN103622981A (zh) * | 2012-08-27 | 2014-03-12 | 康阳润和(北京)医药科技有限公司 | 复方甘草酸苷口服液体制剂及其制备方法 |
CN102871958A (zh) * | 2012-09-24 | 2013-01-16 | 罗诚 | 一种含甘草酸单铵化合物药物组合物及其制备方法 |
CN103860483A (zh) * | 2012-12-13 | 2014-06-18 | 北京京卫信康医药科技发展有限公司 | 复方甘草酸苷类冻干粉针注射剂及其制备方法 |
CN105497049A (zh) * | 2016-03-07 | 2016-04-20 | 闫泽旭 | 一种复方甘草酸苷的共晶组合物 |
CN109613145A (zh) * | 2018-11-20 | 2019-04-12 | 远大医药(中国)有限公司 | 一种复方甘草片分析方法 |
CN111803442B (zh) * | 2020-06-28 | 2022-06-14 | 广州一品红制药有限公司 | 一种用于提高甘草酸单铵s液体剂型生物利用度的稳定剂及其应用 |
CN113197871A (zh) * | 2021-04-25 | 2021-08-03 | 海南通用康力制药有限公司 | 一种注射用复方甘草酸单铵s及其生产工艺 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1742744A (zh) * | 2004-06-09 | 2006-03-08 | 贵阳云岩西创药物科技开发有限公司 | 复方甘草酸单铵粉针制剂及其制备方法 |
-
2008
- 2008-06-27 CN CN2008101157160A patent/CN101317852B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1742744A (zh) * | 2004-06-09 | 2006-03-08 | 贵阳云岩西创药物科技开发有限公司 | 复方甘草酸单铵粉针制剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101317852A (zh) | 2008-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101317852B (zh) | 一种复方甘草酸苷类粉针注射剂及其制备方法 | |
CN101716149B (zh) | 一种新的前体药物制剂 | |
CN102302463A (zh) | 注射用兰索拉唑冻干粉针剂及制备方法 | |
CN103860483A (zh) | 复方甘草酸苷类冻干粉针注射剂及其制备方法 | |
CN101756915B (zh) | 盐酸替罗非班冻干粉针注射剂及制备方法 | |
CN102525963B (zh) | 一种硫酸奈替米星冻干粉针及其制备方法 | |
CN105663127B (zh) | 注射用冷冻干燥法莫替丁组合物 | |
CN103142515B (zh) | 一种细辛脑注射剂及其制备方法 | |
CN101270101B (zh) | 炎琥宁及其冻干粉针剂的制备方法 | |
CN102138909B (zh) | 门冬酰胺酶冻干粉针剂及其制备方法以及门冬酰胺酶溶解液 | |
CN103040767B (zh) | 稳定的注射用穿琥宁冷冻干燥粉针剂 | |
CN100528141C (zh) | 注射用盐酸川芎嗪冻干剂及其制备方法 | |
CN100366250C (zh) | 长春西汀冻干粉针制剂及其制备工艺 | |
EP3040067A1 (en) | Chlorogenic acid powder-injection and preparation method thereof | |
CN100386079C (zh) | 一种抑制血小板凝聚的注射用粉针及其制备方法 | |
CN103142513B (zh) | 一种注射用消旋2-(α-羟基戊基)苯甲酸盐冻干粉针及其制备方法 | |
CN104666253B (zh) | 注射用克林霉素磷酸酯粉针剂药物组合物和制法 | |
CN104721153B (zh) | 注射用氨甲苯酸冷冻干燥粉针剂药物组合物 | |
CN105030702B (zh) | 一种含肝素钠药物组合物及其制备方法 | |
CN100367961C (zh) | 盐酸替罗非班冻干粉针注射剂及其制备方法 | |
CN104800172A (zh) | 注射用卡络磺钠粉针剂和制法 | |
CN113521244B (zh) | 一种阿加曲班注射剂及其制备方法 | |
CN1951388A (zh) | 注射用倍他米松磷酸钠粉针剂及制备方法 | |
CN103565747B (zh) | 一种埃索美拉唑药物组合物及其制备方法 | |
CN101327202B (zh) | 注射用维生素k1冻干粉针及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20090206 Address after: Room 301, east gate, building 2, building 1, four street, Haidian District, Beijing Applicant after: Zhang Yong Address before: Room 301, east gate, building 2, building 1, four street, Haidian District, Beijing Applicant before: Beijing Jingwei Xinkang Medical Technology Development Co., Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: ZHANG YONG Free format text: FORMER OWNER: BEIJING JINGWEIXINKANG MEDICINE SCIENCE DEVELOPMENT CO., LTD. Effective date: 20090206 |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING JINGWEI XINKANG MEDICAL TECHNOLOGY DEVELOP Free format text: FORMER OWNER: ZHANG YONG Effective date: 20110715 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100085 ROOM 301, EAST UNIT, BUILDING 2, YARD 1, SHANGDI STREET 4, HAIDIAN DISTRICT, BEIJING TO: 100085 ROOM 301, BUILDING 2, YARD 1, SHANGDI STREET 4, HAIDIAN DISTRICT, BEIJING |
|
TR01 | Transfer of patent right |
Effective date of registration: 20110715 Address after: 100085, room 2, building 301, No.1 street, four street, Beijing, Haidian District Patentee after: Beijing Jingwei Xinkang Medical Technology Development Co., Ltd. Address before: 100085, Room 301, east gate, building 2, building 1, four street, Haidian District, Beijing Patentee before: Zhang Yong |
|
ASS | Succession or assignment of patent right |
Owner name: TIBET ZHONGWEI XINKANG PHARMACEUTICAL TECHNOLOGY D Free format text: FORMER OWNER: BEIJING JINGWEI XINKANG MEDICAL TECHNOLOGY DEVELOPMENT CO., LTD. Effective date: 20140806 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100085 HAIDIAN, BEIJING TO: 850000 LHASA, TIBET AUTONOMOUS REGION |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140806 Address after: 850000, Tibet autonomous region Lhasa economic and Technological Development Zone A District Tibet West Cold Chain Logistics Co., Ltd. layer 103 room Patentee after: Tibet Zhong Li Xin Kang medical science and Technology Development Co Ltd Address before: 100085, room 2, building 301, No.1 street, four street, Beijing, Haidian District Patentee before: Beijing Jingwei Xinkang Medical Technology Development Co., Ltd. |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20081210 Assignee: Jiangsu Weikang Pharmaceutical Development Co Ltd Assignor: Tibet Zhong Li Xin Kang medical science and Technology Development Co Ltd Contract record no.: 2014990000842 Denomination of invention: Powder injection of compound glycyrrhizic acid glycosides and preparation method thereof Granted publication date: 20100630 License type: Common License Record date: 20141102 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20081210 Assignee: MEDISAN PHARMACEUTICAL CO., LTD. HARBIN Assignor: Tibet Zhong Li Xin Kang medical science and Technology Development Co Ltd Contract record no.: 2015990000588 Denomination of invention: Powder injection of compound glycyrrhizic acid glycosides and preparation method thereof Granted publication date: 20100630 License type: Common License Record date: 20150709 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: 851400 Lhasa economic and Technological Development Zone, Tibet incubator plant floor, the two floor of the contraction of the South 201-1 room, Patentee after: Tibet Xingkang pharmaceutical Limited by Share Ltd Address before: 850000, Tibet Lhasa economic and Technological Development Zone A District, Tibet West Cold Chain Logistics Co., Ltd. layer 103 room Patentee before: Tibet Zhong Li Xin Kang medical science and Technology Development Co Ltd |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20081210 Assignee: MEDISAN PHARMACEUTICAL CO., LTD. HARBIN Assignor: Tibet Xingkang pharmaceutical Limited by Share Ltd Contract record no.: 2016990000228 Denomination of invention: Powder injection of compound glycyrrhizic acid glycosides and preparation method thereof Granted publication date: 20100630 License type: Common License Record date: 20160608 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: MEDISAN PHARMACEUTICAL CO., LTD. HARBIN Assignor: Tibet Xingkang pharmaceutical Limited by Share Ltd Contract record no.: 2016990000228 Date of cancellation: 20161102 |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20081210 Assignee: MEDISAN PHARMACEUTICAL CO., LTD. HARBIN Assignor: Tibet Xingkang pharmaceutical Limited by Share Ltd Contract record no.: 2016990000462 Denomination of invention: Powder injection of compound glycyrrhizic acid glycosides and preparation method thereof Granted publication date: 20100630 License type: Common License Record date: 20161107 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EC01 | Cancellation of recordation of patent licensing contract | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: MEDISAN PHARMACEUTICAL CO., LTD. HARBIN Assignor: Tibet Xingkang pharmaceutical Limited by Share Ltd Contract record no.: 2016990000462 Date of cancellation: 20181109 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20081210 Assignee: MEDISAN PHARMACEUTICAL CO., LTD. HARBIN Assignor: Tibet Xingkang pharmaceutical Limited by Share Ltd Contract record no.: 2018990000296 Denomination of invention: Powder injection of compound glycyrrhizic acid glycosides and preparation method thereof Granted publication date: 20100630 License type: Common License Record date: 20181113 |